Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activat...
Uložené v:
| Vydané v: | Journal of experimental & clinical cancer research Ročník 38; číslo 1; s. 255 - 12 |
|---|---|
| Hlavný autor: | |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
13.06.2019
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1756-9966, 0392-9078, 1756-9966 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers. |
|---|---|
| AbstractList | Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers. Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers.Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers. Abstract Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers. |
| ArticleNumber | 255 |
| Audience | Academic |
| Author | Rotte, Anand |
| Author_xml | – sequence: 1 givenname: Anand surname: Rotte fullname: Rotte, Anand email: anand.rotte@gmail.com, anand.rotte@nevro.com organization: Clinical & Regulatory Affairs, Nevro Corp |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31196207$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAUhSNURB_wA9igSEiITYrt-DHegEbDq9JIsChry7GvZzwkdrEzSPTX43RKO1MB8iKW851z45NzWh2FGKCqnmN0jvGMv8m4RZQ3CMsGEyab60fVCRaMN1JyfrS3P65Oc94gxLHE8kl13GIsOUHipHq3iEPngx59DHV09eJyOW9orYOtv75vcN310XyHlGsXUz0m0OMAYZxIo4OB9LR67HSf4dnt86z69vHD5eJzs_zy6WIxXzZGIDQ2AI7ItpsRDdQKJqQD4WwnWsKR4NRaY7g0RlPMDDXgWKdxhzgXVFthOWrPqoudr416o66SH3T6paL26uYgppXSafSmB2Vn0LWCupnpOCWskwwQ1cYhQyRjVhSvtzuvq203gDXlQkn3B6aHb4Jfq1X8qTjjQmJaDF7fGqT4Ywt5VIPPBvpeB4jbrAhhiFOKES_oywfoJm5TKFEVipIZkhK399RKlwv44GKZayZTNWeyJIQQm7zO_0KVZWHwplTD-XJ-IHi1J1iD7sd1jv12-tn5EHyxn8hdFH96UgC8A0yKOSdwdwhGauqi2nVRlS6qqYvqumjEA43x403Rymf7_r9KslPmMiWsIN2H9m_Rby32714 |
| CitedBy_id | crossref_primary_10_1016_j_apsb_2024_08_004 crossref_primary_10_1080_17474124_2021_1853527 crossref_primary_10_3390_biomedicines9091277 crossref_primary_10_3390_ijms252111676 crossref_primary_10_3389_fmed_2021_759605 crossref_primary_10_1016_j_canlet_2025_217614 crossref_primary_10_1136_jitc_2023_007433 crossref_primary_10_1631_jzus_B2300492 crossref_primary_10_1016_j_canlet_2025_217616 crossref_primary_10_1136_jitc_2024_008923 crossref_primary_10_3389_fimmu_2022_795972 crossref_primary_10_7717_peerj_15476 crossref_primary_10_1002_cam4_6342 crossref_primary_10_3389_fimmu_2022_871362 crossref_primary_10_3390_ijms21218305 crossref_primary_10_1177_17588359231220510 crossref_primary_10_1155_2022_3051907 crossref_primary_10_3389_fcell_2021_736298 crossref_primary_10_1097_MD_0000000000037950 crossref_primary_10_3389_pore_2022_1610199 crossref_primary_10_3390_ijms23063087 crossref_primary_10_2217_fon_2021_0529 crossref_primary_10_3390_cancers14205153 crossref_primary_10_3390_healthcare10040694 crossref_primary_10_3390_cancers13081959 crossref_primary_10_3390_epigenomes5030016 crossref_primary_10_3389_fcell_2021_795133 crossref_primary_10_3389_fcimb_2022_953718 crossref_primary_10_1016_j_pharmthera_2019_107456 crossref_primary_10_1016_j_prp_2025_155864 crossref_primary_10_1016_j_critrevonc_2022_103750 crossref_primary_10_3389_fonc_2022_755053 crossref_primary_10_1016_j_canlet_2020_12_043 crossref_primary_10_1016_j_critrevonc_2021_103573 crossref_primary_10_3390_ijms21124361 crossref_primary_10_1016_j_lungcan_2023_107322 crossref_primary_10_1038_s41419_023_06389_5 crossref_primary_10_1007_s00432_022_04159_y crossref_primary_10_1134_S1022795422040020 crossref_primary_10_3390_cancers17061008 crossref_primary_10_1016_j_intimp_2022_108813 crossref_primary_10_1038_s43018_024_00729_w crossref_primary_10_1016_j_heliyon_2023_e13599 crossref_primary_10_3389_fimmu_2025_1544104 crossref_primary_10_1038_s41392_022_01136_2 crossref_primary_10_4103_aja202186 crossref_primary_10_1007_s10528_023_10483_w crossref_primary_10_3389_fgene_2021_771253 crossref_primary_10_3389_fonc_2022_1094248 crossref_primary_10_1016_j_intimp_2024_113952 crossref_primary_10_1158_1078_0432_CCR_21_2681 crossref_primary_10_3389_fimmu_2021_627932 crossref_primary_10_3390_cancers15030563 crossref_primary_10_1016_j_ebiom_2021_103624 crossref_primary_10_4049_jimmunol_2200371 crossref_primary_10_1016_j_intimp_2023_111055 crossref_primary_10_1016_j_copbio_2020_01_006 crossref_primary_10_1186_s12935_021_02100_w crossref_primary_10_3389_fgene_2022_1053263 crossref_primary_10_1007_s44178_023_00035_y crossref_primary_10_3389_fimmu_2021_676181 crossref_primary_10_1016_j_canlet_2020_03_013 crossref_primary_10_3389_fmolb_2023_1157970 crossref_primary_10_3389_fonc_2021_693321 crossref_primary_10_1186_s40246_024_00624_6 crossref_primary_10_1007_s12094_022_02913_9 crossref_primary_10_1002_iid3_1099 crossref_primary_10_1007_s00432_022_04399_y crossref_primary_10_1016_j_cellimm_2024_104842 crossref_primary_10_1016_j_prp_2024_155345 crossref_primary_10_1080_17568919_2025_2527604 crossref_primary_10_1016_j_critrevonc_2022_103893 crossref_primary_10_1016_j_apsb_2021_02_007 crossref_primary_10_1007_s11538_021_00933_0 crossref_primary_10_1016_j_omtm_2021_01_002 crossref_primary_10_3389_fimmu_2023_1113312 crossref_primary_10_3389_fcell_2024_1453630 crossref_primary_10_1186_s12957_025_03752_y crossref_primary_10_2147_CMAR_S474348 crossref_primary_10_1016_j_gene_2022_147052 crossref_primary_10_3390_biology12020218 crossref_primary_10_1002_cam4_4190 crossref_primary_10_1038_s41419_022_05526_w crossref_primary_10_3390_biomedicines10030655 crossref_primary_10_1177_00045632241312629 crossref_primary_10_1016_S0007_4551_22_00234_X crossref_primary_10_3389_fphar_2023_1103547 crossref_primary_10_1007_s12094_021_02659_w crossref_primary_10_1016_j_hbpd_2021_06_010 crossref_primary_10_1186_s40537_023_00752_1 crossref_primary_10_1038_s41392_023_01450_3 crossref_primary_10_3389_fgene_2022_918977 crossref_primary_10_1038_s41423_024_01232_z crossref_primary_10_1002_advs_202400920 crossref_primary_10_1093_abt_tbaa003 crossref_primary_10_3390_cancers13194797 crossref_primary_10_1002_advs_202403077 crossref_primary_10_1186_s12951_023_01841_2 crossref_primary_10_1016_j_heliyon_2024_e24559 crossref_primary_10_3390_ph14050476 crossref_primary_10_1097_IOP_0000000000001853 crossref_primary_10_3892_ijo_2022_5302 crossref_primary_10_1002_cam4_5698 crossref_primary_10_1016_j_ccell_2024_03_001 crossref_primary_10_1007_s10495_025_02119_8 crossref_primary_10_3389_fimmu_2022_1031746 crossref_primary_10_3389_fonc_2021_636681 crossref_primary_10_3389_fphar_2025_1478331 crossref_primary_10_3390_vaccines13040344 crossref_primary_10_1038_s41388_021_01677_w crossref_primary_10_1158_1078_0432_CCR_23_3162 crossref_primary_10_3389_fonc_2021_803133 crossref_primary_10_3389_fimmu_2025_1645019 crossref_primary_10_1186_s13046_021_02111_5 crossref_primary_10_1002_cam4_70899 crossref_primary_10_1016_j_artmed_2023_102681 crossref_primary_10_1002_adma_202003368 crossref_primary_10_1186_s40360_024_00821_y crossref_primary_10_3389_fendo_2023_1201198 crossref_primary_10_32604_biocell_2023_029094 crossref_primary_10_3390_cancers12061660 crossref_primary_10_1002_ctd2_70001 crossref_primary_10_3390_biology10111178 crossref_primary_10_1038_s41598_023_30695_9 crossref_primary_10_1016_j_media_2024_103097 crossref_primary_10_1038_s41392_021_00823_w crossref_primary_10_3390_clinpract15010021 crossref_primary_10_1016_j_ejca_2021_07_015 crossref_primary_10_1177_09636897211041587 crossref_primary_10_1186_s13046_019_1426_2 crossref_primary_10_2217_cer_2020_0236 crossref_primary_10_1016_j_jim_2020_112795 crossref_primary_10_3390_cancers17050880 crossref_primary_10_1080_13543784_2021_1972969 crossref_primary_10_1158_1078_0432_CCR_21_3304 crossref_primary_10_3389_fonc_2022_1031094 crossref_primary_10_1186_s12964_025_02270_4 crossref_primary_10_1097_PAI_0000000000001227 crossref_primary_10_1007_s12325_020_01386_y crossref_primary_10_1080_14796694_2025_2530378 crossref_primary_10_3390_ijms232213961 crossref_primary_10_3390_ph15060711 crossref_primary_10_1007_s10555_020_09887_6 crossref_primary_10_1002_cam4_5475 crossref_primary_10_1007_s43152_023_00047_w crossref_primary_10_1016_j_immuni_2024_02_007 crossref_primary_10_3389_fimmu_2023_1138743 crossref_primary_10_1186_s13578_023_01139_8 crossref_primary_10_3390_pharmaceutics15020428 crossref_primary_10_1016_j_jtho_2024_09_1439 crossref_primary_10_1038_s41598_024_67547_z crossref_primary_10_1159_000512326 crossref_primary_10_1007_s00262_020_02593_w crossref_primary_10_1016_j_compbiomed_2024_108253 crossref_primary_10_1080_2162402X_2020_1746113 crossref_primary_10_2147_PGPM_S391756 crossref_primary_10_3389_fimmu_2023_1012841 crossref_primary_10_1016_j_ejphar_2021_173867 crossref_primary_10_1111_cas_15139 crossref_primary_10_1371_journal_pone_0279119 crossref_primary_10_3389_fonc_2021_621050 crossref_primary_10_3390_cells10082044 crossref_primary_10_1080_08923973_2023_2261146 crossref_primary_10_3390_biom11050637 crossref_primary_10_3389_fphar_2022_928369 crossref_primary_10_1177_1758835920947976 crossref_primary_10_1146_annurev_med_042220_021121 crossref_primary_10_3390_ijms24010250 crossref_primary_10_3390_ijms222212565 crossref_primary_10_1016_j_wneu_2020_09_031 crossref_primary_10_1038_s41392_021_00868_x crossref_primary_10_1007_s12291_024_01201_3 crossref_primary_10_1002_advs_202400702 crossref_primary_10_1016_j_ccmp_2021_100005 crossref_primary_10_1080_09273948_2021_1890133 crossref_primary_10_1038_s41467_022_35345_8 crossref_primary_10_1177_1756284820948773 crossref_primary_10_1158_0008_5472_CAN_23_2244 crossref_primary_10_1016_j_eswa_2025_126566 crossref_primary_10_1186_s12967_025_06842_3 crossref_primary_10_1016_j_canlet_2024_216766 crossref_primary_10_3390_ijms241612622 crossref_primary_10_1186_s40425_019_0795_6 crossref_primary_10_3390_ph17070964 crossref_primary_10_3892_mmr_2025_13515 crossref_primary_10_3389_fgene_2021_612011 crossref_primary_10_1080_1750743X_2025_2536454 crossref_primary_10_3389_fphar_2023_1230824 crossref_primary_10_1002_cac2_12153 crossref_primary_10_1111_jog_15234 crossref_primary_10_1111_jcmm_70482 crossref_primary_10_12677_acm_2025_1551481 crossref_primary_10_1136_jitc_2022_004711 crossref_primary_10_1080_1061186X_2019_1669042 crossref_primary_10_1080_17512433_2023_2219446 crossref_primary_10_1080_17474124_2022_2150841 crossref_primary_10_3390_cancers14041054 crossref_primary_10_1016_j_gene_2020_144888 crossref_primary_10_1186_s12943_024_02068_x crossref_primary_10_3389_fimmu_2025_1562875 crossref_primary_10_2147_IJGM_S411511 crossref_primary_10_3389_fimmu_2022_740960 crossref_primary_10_3389_fimmu_2022_826164 crossref_primary_10_1080_17474124_2022_2064273 crossref_primary_10_1097_PAI_0000000000000978 crossref_primary_10_1158_1078_0432_CCR_21_1046 crossref_primary_10_1016_j_heliyon_2023_e19147 crossref_primary_10_1097_FTD_0000000000001228 crossref_primary_10_3390_ijms26072923 crossref_primary_10_3390_molecules25204641 crossref_primary_10_1002_hsr2_202 crossref_primary_10_1016_j_intimp_2024_112582 crossref_primary_10_1007_s11684_022_0927_0 crossref_primary_10_1186_s12929_023_00952_0 crossref_primary_10_3389_fimmu_2025_1479550 crossref_primary_10_1186_s12885_021_08054_6 crossref_primary_10_1186_s13046_024_03187_5 crossref_primary_10_3389_fimmu_2022_959705 crossref_primary_10_3390_ijms221810009 crossref_primary_10_1080_14712598_2021_1936494 crossref_primary_10_3390_cancers12071796 crossref_primary_10_1016_j_tranon_2024_102216 crossref_primary_10_1080_21655979_2021_1918538 crossref_primary_10_1016_j_lfs_2023_122396 crossref_primary_10_2217_fon_2020_0967 crossref_primary_10_1007_s00262_020_02579_8 crossref_primary_10_3389_fmed_2025_1596120 crossref_primary_10_1016_j_intimp_2023_109827 crossref_primary_10_3390_biomedicines11072086 crossref_primary_10_3389_fonc_2021_723238 crossref_primary_10_1080_08830185_2024_2333275 crossref_primary_10_3389_fimmu_2022_888650 crossref_primary_10_3390_ijms24044044 crossref_primary_10_3389_fimmu_2020_01301 crossref_primary_10_3390_cancers12082204 crossref_primary_10_1016_j_ygeno_2023_110646 crossref_primary_10_1080_13543784_2021_1854725 crossref_primary_10_1186_s12964_023_01438_0 crossref_primary_10_3390_cancers14153788 crossref_primary_10_1080_14728214_2020_1852215 crossref_primary_10_1186_s12943_024_02089_6 crossref_primary_10_2147_OTT_S271955 crossref_primary_10_3389_fonc_2021_678694 crossref_primary_10_3390_biom14050523 crossref_primary_10_1007_s10637_022_01232_8 crossref_primary_10_3390_cancers16244219 crossref_primary_10_1186_s40164_025_00636_5 crossref_primary_10_3389_fimmu_2025_1575627 crossref_primary_10_3389_fimmu_2023_1105489 crossref_primary_10_1080_14728222_2021_1976142 crossref_primary_10_3390_ijms21238993 crossref_primary_10_1093_oncolo_oyae192 crossref_primary_10_3389_fimmu_2024_1355812 crossref_primary_10_1158_2326_6066_CIR_20_0304 crossref_primary_10_3389_fcell_2021_633927 crossref_primary_10_1016_j_lfs_2021_119426 crossref_primary_10_1155_2021_8970173 crossref_primary_10_1016_j_critrevonc_2023_104070 crossref_primary_10_3390_cancers15071974 crossref_primary_10_1080_21645515_2021_1980315 crossref_primary_10_1038_s41420_024_02182_1 crossref_primary_10_1080_2162402X_2023_2217735 crossref_primary_10_2174_012212697X308365240529100442 crossref_primary_10_3389_fonc_2023_1083956 crossref_primary_10_1371_journal_pone_0243145 crossref_primary_10_1016_j_biopha_2024_116132 crossref_primary_10_1038_s41437_022_00533_1 crossref_primary_10_1016_j_intimp_2024_113365 crossref_primary_10_1007_s00262_021_03022_2 crossref_primary_10_3390_ijms21113949 crossref_primary_10_1016_j_phrs_2020_104745 crossref_primary_10_1016_j_apsb_2022_09_004 crossref_primary_10_3389_fmed_2025_1586552 crossref_primary_10_3389_fimmu_2022_1070961 crossref_primary_10_1172_JCI137750 crossref_primary_10_3390_cancers16162778 crossref_primary_10_3389_fimmu_2025_1631273 crossref_primary_10_1007_s12272_024_01524_y crossref_primary_10_1016_j_semcancer_2020_01_003 crossref_primary_10_3390_cancers12092691 crossref_primary_10_3390_cancers13174322 crossref_primary_10_1038_s41577_023_00867_9 crossref_primary_10_3389_fonc_2021_686156 crossref_primary_10_3390_ijms26010088 crossref_primary_10_1002_cam4_5750 crossref_primary_10_1038_s41698_024_00743_2 crossref_primary_10_1134_S1990519X21050102 crossref_primary_10_1016_j_addr_2021_05_027 crossref_primary_10_1056_NEJMe2116892 crossref_primary_10_3390_cancers12010079 crossref_primary_10_4049_jimmunol_2100367 crossref_primary_10_3389_fonc_2021_715677 crossref_primary_10_3389_fimmu_2023_1181051 crossref_primary_10_3390_cells10113231 crossref_primary_10_1038_s41587_024_02535_2 crossref_primary_10_1080_14656566_2022_2106128 crossref_primary_10_3390_cancers12092565 crossref_primary_10_1080_17474086_2025_2469720 crossref_primary_10_3389_fimmu_2023_1280741 crossref_primary_10_3390_cancers13235999 crossref_primary_10_1038_s41419_020_2252_3 crossref_primary_10_1002_med_21700 crossref_primary_10_1093_oncolo_oyac099 crossref_primary_10_1038_s41598_024_77638_6 crossref_primary_10_1371_journal_pone_0306869 crossref_primary_10_18027_2224_5057_2024_013 crossref_primary_10_1186_s12943_024_02156_y crossref_primary_10_1186_s13046_025_03394_8 crossref_primary_10_2217_imt_2023_0023 crossref_primary_10_3390_biomedicines12091979 crossref_primary_10_7717_peerj_15088 crossref_primary_10_1002_ange_202116669 crossref_primary_10_1002_tox_24208 crossref_primary_10_1016_j_semcancer_2019_09_019 crossref_primary_10_1080_21645515_2024_2312599 crossref_primary_10_3390_cancers16193388 crossref_primary_10_1007_s10495_024_01982_1 crossref_primary_10_32604_or_2023_042345 crossref_primary_10_3389_fimmu_2022_746484 crossref_primary_10_1186_s40001_024_02168_w crossref_primary_10_1016_j_heliyon_2024_e34877 crossref_primary_10_3389_fonc_2023_1170397 crossref_primary_10_3389_fimmu_2023_1182030 crossref_primary_10_3390_cancers14246131 crossref_primary_10_1007_s12094_023_03126_4 crossref_primary_10_1038_s43018_022_00357_2 crossref_primary_10_1186_s13045_021_01134_x crossref_primary_10_1016_j_humimm_2024_111210 crossref_primary_10_3389_fimmu_2020_02023 crossref_primary_10_1016_j_soc_2025_01_003 crossref_primary_10_1093_qjmed_hcab014 crossref_primary_10_1177_1073274820945975 crossref_primary_10_1515_biol_2021_0094 crossref_primary_10_3390_cancers13092164 crossref_primary_10_2174_0109298673318929240829065611 crossref_primary_10_3390_cancers16111973 crossref_primary_10_3390_pharmaceutics14051046 crossref_primary_10_3389_fonc_2022_912699 crossref_primary_10_1002_iju5_12173 crossref_primary_10_1007_s44446_025_00018_2 crossref_primary_10_3389_fgene_2022_843579 crossref_primary_10_1007_s00262_024_03734_1 crossref_primary_10_3390_vaccines10091448 crossref_primary_10_1016_j_ejpb_2023_02_002 crossref_primary_10_3390_biomedicines12010217 crossref_primary_10_3390_biomedicines13030711 crossref_primary_10_1136_jitc_2020_001966 crossref_primary_10_3389_fonc_2021_648052 crossref_primary_10_1016_j_chembiol_2024_07_004 crossref_primary_10_3390_ijms25137252 crossref_primary_10_1002_pro6_1165 crossref_primary_10_1186_s12957_020_01933_5 crossref_primary_10_1007_s40265_022_01761_9 crossref_primary_10_3389_fimmu_2022_1056397 crossref_primary_10_1080_14796694_2025_2558287 crossref_primary_10_2147_OTT_S324641 crossref_primary_10_1155_2022_8556593 crossref_primary_10_1080_19420862_2020_1725365 crossref_primary_10_2217_imt_2019_0120 crossref_primary_10_3389_fimmu_2022_940930 crossref_primary_10_1007_s10787_021_00796_w crossref_primary_10_1186_s12967_023_03929_7 crossref_primary_10_1038_s44276_023_00035_5 crossref_primary_10_1631_jzus_B2200195 crossref_primary_10_3390_ijms241915016 crossref_primary_10_1016_j_cytogfr_2021_10_005 crossref_primary_10_1016_j_heliyon_2024_e28332 crossref_primary_10_3389_fgene_2023_1108167 crossref_primary_10_3389_fimmu_2023_1191866 crossref_primary_10_2147_JHC_S453249 crossref_primary_10_1016_j_intimp_2020_106628 crossref_primary_10_1038_s41598_024_51804_2 crossref_primary_10_3390_ijms23052638 crossref_primary_10_1007_s12539_025_00719_1 crossref_primary_10_1038_s41598_024_83719_3 crossref_primary_10_1016_j_cellimm_2022_104532 crossref_primary_10_1038_s41572_020_00240_3 crossref_primary_10_1007_s00262_020_02530_x crossref_primary_10_1016_j_biopha_2022_112949 crossref_primary_10_3389_fonc_2023_1127768 crossref_primary_10_1038_s41392_024_01823_2 crossref_primary_10_15789_1563_0625_ICI_2923 crossref_primary_10_1038_s41420_022_00983_w crossref_primary_10_1186_s13046_021_02076_5 crossref_primary_10_3389_fonc_2023_1038710 crossref_primary_10_3390_ijms23137068 crossref_primary_10_1007_s40264_021_01086_8 crossref_primary_10_3390_ijms21155337 crossref_primary_10_1136_jitc_2024_009662 crossref_primary_10_3390_ijms21030878 crossref_primary_10_1002_mco2_437 crossref_primary_10_3389_fimmu_2022_1022190 crossref_primary_10_3390_ijms22158037 crossref_primary_10_3390_jcm12051715 crossref_primary_10_3390_jcm11041019 crossref_primary_10_3390_jcm12072636 crossref_primary_10_3390_genes11060703 crossref_primary_10_1016_j_intimp_2020_106972 crossref_primary_10_1038_s41419_022_04688_x crossref_primary_10_1177_17588359231189436 crossref_primary_10_1080_17474124_2021_1973431 crossref_primary_10_1002_mc_23401 crossref_primary_10_1038_s41598_021_01572_0 crossref_primary_10_1080_17474124_2021_1845141 crossref_primary_10_37349_etat_2025_1002313 crossref_primary_10_1155_2022_8232024 crossref_primary_10_1038_s44321_025_00297_1 crossref_primary_10_1007_s12032_024_02411_8 crossref_primary_10_3390_jcm10091919 crossref_primary_10_1016_j_intimp_2025_115432 crossref_primary_10_3390_cancers14143332 crossref_primary_10_1097_ID9_0000000000000175 crossref_primary_10_1016_j_pep_2024_106522 crossref_primary_10_1002_jso_26604 crossref_primary_10_3389_fgene_2022_1002699 crossref_primary_10_1016_j_jbc_2022_102013 crossref_primary_10_3389_fendo_2022_931647 crossref_primary_10_2147_IJGM_S353576 crossref_primary_10_3389_fphar_2023_1151032 crossref_primary_10_1016_j_bioorg_2023_106837 crossref_primary_10_3389_fimmu_2022_864244 crossref_primary_10_1007_s12672_024_01236_1 crossref_primary_10_1080_2162402X_2021_1987636 crossref_primary_10_3390_cancers11111756 crossref_primary_10_1038_s41392_020_0116_z crossref_primary_10_1186_s12964_024_01711_w crossref_primary_10_1016_j_critrevonc_2024_104403 crossref_primary_10_1371_journal_pone_0275777 crossref_primary_10_1186_s13046_020_01818_1 crossref_primary_10_1200_JCO_24_02239 crossref_primary_10_3389_fonc_2021_706586 crossref_primary_10_3389_fgene_2022_1001374 crossref_primary_10_1038_s41598_022_15205_7 crossref_primary_10_1038_s41598_023_47377_1 crossref_primary_10_3389_fimmu_2023_1139268 crossref_primary_10_1016_j_pharmthera_2024_108667 crossref_primary_10_1007_s10142_025_01586_1 crossref_primary_10_1016_j_jconrel_2024_07_023 crossref_primary_10_1002_adhm_202400512 crossref_primary_10_1002_advs_202102500 crossref_primary_10_1007_s10528_023_10446_1 crossref_primary_10_1080_2162402X_2024_2370544 crossref_primary_10_3390_ijms20174320 crossref_primary_10_3748_wjg_v26_i33_4900 crossref_primary_10_1177_10732748221121382 crossref_primary_10_3390_cancers12020361 crossref_primary_10_1016_j_jiec_2020_11_015 crossref_primary_10_3389_fphar_2025_1646818 crossref_primary_10_3233_CBM_210114 crossref_primary_10_1016_j_prp_2022_154241 crossref_primary_10_1038_s41420_022_00996_5 crossref_primary_10_1016_j_tranon_2024_101955 crossref_primary_10_1038_s41467_024_45160_y crossref_primary_10_1016_j_intimp_2020_106700 crossref_primary_10_3389_fimmu_2023_1321051 crossref_primary_10_2174_0929867329666220819115849 crossref_primary_10_1158_2159_8290_CD_20_1248 crossref_primary_10_1007_s13577_020_00393_z crossref_primary_10_3390_cells9091987 crossref_primary_10_3390_cells9081823 crossref_primary_10_1111_1759_7714_15455 crossref_primary_10_1186_s12964_020_00599_6 crossref_primary_10_1016_j_omton_2024_200885 crossref_primary_10_3389_fimmu_2025_1578986 crossref_primary_10_1186_s13045_023_01445_1 crossref_primary_10_1007_s00432_023_04737_8 crossref_primary_10_1038_s41392_024_01943_9 crossref_primary_10_1042_BSR20201248 crossref_primary_10_1186_s10020_024_00780_4 crossref_primary_10_3390_cancers13164233 crossref_primary_10_1038_s42003_023_05753_7 crossref_primary_10_3390_cancers12071807 crossref_primary_10_1055_a_1166_4330 crossref_primary_10_3389_fonc_2020_559596 crossref_primary_10_3390_cancers13102366 crossref_primary_10_1089_mab_2021_0004 crossref_primary_10_2147_JIR_S344554 crossref_primary_10_3390_vaccines9050509 crossref_primary_10_1111_imm_13785 crossref_primary_10_3389_fimmu_2022_843106 crossref_primary_10_1126_sciimmunol_abf4034 crossref_primary_10_3389_fimmu_2023_1127071 crossref_primary_10_1016_j_gene_2023_147887 crossref_primary_10_1177_1120672120930688 crossref_primary_10_1080_02648725_2022_2147683 crossref_primary_10_1016_j_jhealeco_2025_102976 crossref_primary_10_1038_s42003_024_05765_x crossref_primary_10_1111_jcmm_17494 crossref_primary_10_1186_s12943_024_01956_6 crossref_primary_10_1007_s13193_024_01977_z crossref_primary_10_1080_13543784_2020_1769066 crossref_primary_10_1016_j_intimp_2024_111947 crossref_primary_10_3389_fonc_2021_712788 crossref_primary_10_3390_cancers14040892 crossref_primary_10_3390_cancers14133164 crossref_primary_10_3390_cancers15030824 crossref_primary_10_1016_j_bbcan_2022_188738 crossref_primary_10_1158_2326_6066_CIR_22_0110 crossref_primary_10_1016_j_biocel_2022_106309 crossref_primary_10_3390_ijms21145009 crossref_primary_10_3390_cancers12123630 crossref_primary_10_1186_s12935_019_0955_2 crossref_primary_10_3389_fimmu_2023_1323797 crossref_primary_10_3390_cancers13236067 crossref_primary_10_1016_j_semcancer_2020_07_001 crossref_primary_10_3390_jcm13195876 crossref_primary_10_1016_j_annonc_2020_04_474 crossref_primary_10_1155_2022_6378567 crossref_primary_10_3892_ol_2025_15108 crossref_primary_10_1007_s00018_024_05573_w crossref_primary_10_1016_j_phrs_2023_106701 crossref_primary_10_7717_peerj_14529 crossref_primary_10_3390_cancers14133058 crossref_primary_10_1016_S0140_6736_24_02135_4 crossref_primary_10_1186_s12967_022_03670_7 crossref_primary_10_3389_fimmu_2023_1094009 crossref_primary_10_3389_fonc_2021_635007 crossref_primary_10_1186_s12935_021_01824_z crossref_primary_10_1016_j_prp_2025_155811 crossref_primary_10_3389_fimmu_2022_915094 crossref_primary_10_1053_j_semnuclmed_2022_08_011 crossref_primary_10_1186_s12943_025_02390_y crossref_primary_10_1007_s00761_025_01778_1 crossref_primary_10_3389_fimmu_2024_1440830 crossref_primary_10_1080_13543784_2021_1948532 crossref_primary_10_3390_jcm8101596 crossref_primary_10_1002_cbin_11955 crossref_primary_10_1186_s12957_023_03212_5 crossref_primary_10_1186_s40001_024_01901_9 crossref_primary_10_1186_s13287_023_03413_5 crossref_primary_10_1177_17588359241292264 crossref_primary_10_3390_cancers15030971 crossref_primary_10_1016_j_drup_2022_100907 crossref_primary_10_1038_s41598_024_64261_8 crossref_primary_10_3389_fonc_2025_1551061 crossref_primary_10_1007_s12672_025_01803_0 crossref_primary_10_1097_IOP_0000000000001543 crossref_primary_10_1155_2021_5669635 crossref_primary_10_12677_PI_2021_103015 crossref_primary_10_3390_cancers15133499 crossref_primary_10_3389_fonc_2021_731896 crossref_primary_10_1016_j_ctarc_2022_100641 crossref_primary_10_1186_s13073_023_01170_x crossref_primary_10_1007_s12094_024_03742_8 crossref_primary_10_1016_j_omto_2021_06_016 crossref_primary_10_3390_cancers17030431 crossref_primary_10_1016_j_ejca_2023_113501 crossref_primary_10_3390_cancers14061580 crossref_primary_10_3892_ol_2025_15128 crossref_primary_10_3389_fonc_2020_550987 crossref_primary_10_1093_abt_tbad029 crossref_primary_10_3390_ani13121888 crossref_primary_10_1007_s40005_023_00633_y crossref_primary_10_1136_bmjonc_2024_000615 crossref_primary_10_1186_s12885_024_12777_7 crossref_primary_10_3389_fonc_2023_999193 crossref_primary_10_3390_cells14130985 crossref_primary_10_1016_j_biopha_2025_118023 crossref_primary_10_1002_smll_202401631 crossref_primary_10_1371_journal_pbio_3002943 crossref_primary_10_3390_ijms22137106 crossref_primary_10_1007_s12672_023_00758_4 crossref_primary_10_1016_j_intimp_2021_107929 crossref_primary_10_1016_j_tig_2023_07_005 crossref_primary_10_1146_annurev_chembioeng_100522_102155 crossref_primary_10_3390_ijms23126664 crossref_primary_10_1016_j_bbrc_2024_150832 crossref_primary_10_1186_s13046_021_01987_7 crossref_primary_10_3390_cancers14112664 crossref_primary_10_3390_cancers15215232 crossref_primary_10_1016_j_cej_2021_129774 crossref_primary_10_1038_s41388_021_01883_6 crossref_primary_10_3389_fonc_2023_1153066 crossref_primary_10_3389_fgene_2022_1100787 crossref_primary_10_3389_fnano_2022_911063 crossref_primary_10_1038_s41417_025_00950_4 crossref_primary_10_3389_fimmu_2022_932938 crossref_primary_10_1158_1078_0432_CCR_25_0618 crossref_primary_10_1111_cbdd_14613 crossref_primary_10_1002_iid3_626 crossref_primary_10_1016_j_nut_2022_111829 crossref_primary_10_1016_j_tranon_2022_101426 crossref_primary_10_12998_wjcc_v12_i8_1510 crossref_primary_10_3390_cancers14112658 crossref_primary_10_1080_14737159_2020_1724785 crossref_primary_10_1111_imm_13720 crossref_primary_10_1007_s12672_024_01388_0 crossref_primary_10_1016_j_apsb_2021_10_003 crossref_primary_10_1016_j_oor_2024_100650 crossref_primary_10_1016_j_tranon_2024_102086 crossref_primary_10_3390_ph15030335 crossref_primary_10_1016_j_mtbio_2025_102133 crossref_primary_10_1155_2022_7904982 crossref_primary_10_3390_immuno4030013 crossref_primary_10_3390_biomedicines9091075 crossref_primary_10_3390_cancers15102721 crossref_primary_10_1186_s12885_023_11267_6 crossref_primary_10_3389_fonc_2021_658488 crossref_primary_10_1002_idm2_12199 crossref_primary_10_1111_ecc_13268 crossref_primary_10_1080_21645515_2023_2269794 crossref_primary_10_1038_s41598_025_95551_4 crossref_primary_10_3390_ijms22137201 crossref_primary_10_1007_s11864_024_01243_y crossref_primary_10_1016_j_lfs_2022_121138 crossref_primary_10_1002_anie_202116669 crossref_primary_10_1016_j_ctarc_2021_100437 crossref_primary_10_3389_fendo_2022_1075431 crossref_primary_10_3389_fimmu_2020_585819 crossref_primary_10_1155_2023_2211942 crossref_primary_10_1007_s00262_022_03201_9 crossref_primary_10_1016_j_rcl_2021_05_010 crossref_primary_10_3389_fimmu_2023_1258291 crossref_primary_10_1016_j_bbcan_2023_188873 crossref_primary_10_1016_j_pharmthera_2020_107786 crossref_primary_10_1016_S0140_6736_20_32598_8 crossref_primary_10_3389_fimmu_2021_734646 crossref_primary_10_3389_fmolb_2022_1039121 crossref_primary_10_3390_cancers16132478 crossref_primary_10_1158_1078_0432_CCR_20_5017 crossref_primary_10_3389_fimmu_2024_1255825 crossref_primary_10_1080_21645515_2024_2365771 crossref_primary_10_1016_j_canlet_2022_215887 crossref_primary_10_1016_j_tranon_2022_101405 crossref_primary_10_3389_fonc_2020_01182 crossref_primary_10_3390_cancers13112567 crossref_primary_10_1002_adfm_202113168 crossref_primary_10_3389_fonc_2025_1511560 crossref_primary_10_3389_fmed_2020_00264 crossref_primary_10_1002_iid3_523 crossref_primary_10_1016_j_intimp_2020_106770 crossref_primary_10_3390_cancers13030440 crossref_primary_10_3390_ijms22126309 crossref_primary_10_3389_fendo_2022_970489 crossref_primary_10_3389_fimmu_2025_1629879 |
| Cites_doi | 10.1038/85330 10.4049/jimmunol.165.3.1352 10.1038/s41591-018-0198-0 10.1093/annonc/mdw692 10.1007/s10555-014-9542-0 10.1016/S1470-2045(16)30624-6 10.1200/JCO.2016.71.9476 10.4049/jimmunol.1490019 10.1084/jem.182.2.459 10.1111/j.1600-065X.2010.00923.x 10.1016/S1074-7613(00)80089-8 10.1189/jlb.1212621 10.1136/annrheumdis-2016-209595 10.1016/S1470-2045(15)00544-6 10.1200/JCO.2017.76.9901 10.1056/NEJMoa1712126 10.1056/NEJMoa1602252 10.1056/NEJMoa1709937 10.1126/science.1160062 10.1007/978-3-319-48066-4 10.1001/jamaoncol.2017.2411 10.1093/annonc/mdu577 10.1016/S1470-2045(18)30062-7 10.1056/NEJMoa1104621 10.1016/S0140-6736(16)32517-X 10.18632/oncotarget.25564 10.1056/NEJMoa1609214 10.1371/journal.pone.0003842 10.1093/annonc/mdx686 10.1016/S1470-2045(16)30126-7 10.1056/NEJMoa1302369 10.1126/science.271.5256.1734 10.4049/jimmunol.170.2.711 10.1016/j.ejca.2016.07.003 10.1016/S1074-7613(00)80406-9 10.1016/S0140-6736(18)31257-1 10.1016/j.cell.2018.09.035 10.1056/NEJMoa1611299 10.1056/NEJMoa1801946 10.1016/S1470-2045(17)30422-9 10.1016/S0140-6736(17)31827-5 10.1056/NEJMoa1003466 10.1200/JCO.19.00315 10.4049/jimmunol.157.11.4762 10.1002/j.1460-2075.1992.tb05481.x 10.1016/S1470-2045(15)70076-8 10.1056/NEJMoa1510665 10.1126/science.aav7062 10.1053/j.seminoncol.2015.05.014 10.1056/NEJMoa1606774 10.1200/JCO.18.01042 10.1186/s13046-018-0937-6 10.1007/978-3-319-48066-4_12 10.1016/1074-7613(95)90125-6 10.1200/JCO.19.00318 10.1016/S1470-2045(17)30428-X 10.1001/jamaoncol.2018.0013 10.1056/NEJMoa1805453 10.1016/S1471-4906(01)01888-9 10.1056/NEJMoa1504030 10.1056/NEJMoa1411087 10.1200/JCO.2016.72.1985 10.1056/NEJMoa1504627 10.1093/annonc/mdy006 10.1146/annurev.immunol.26.021607.090331 10.1016/S1470-2045(18)30700-9 10.1200/JCO.2016.67.9258 10.1002/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P 10.1056/NEJMoa1501824 10.1056/NEJMoa1503093 10.1056/NEJMoa1709684 10.1200/JCO.2016.68.1478 10.14302/issn.2471-2175.jdrt-17-1760 10.1056/NEJMoa1414428 10.1016/S1470-2045(16)30366-7 10.1038/s12276-018-0191-1 10.1016/S0140-6736(16)00561-4 10.1001/jamaoncol.2016.0775 10.1016/j.intimp.2018.06.001 10.1056/NEJMoa1613683 10.1016/S0140-6736(16)00587-0 10.1007/978-1-4939-8958-4_4 10.18632/oncotarget.25627 10.1200/JCO.2017.76.6212 10.1016/S1470-2045(17)30231-0 10.1016/S1470-2045(15)00083-2 10.1016/S2213-2600(18)30420-X 10.1084/jem.20090847 10.1038/35069118 10.1016/j.ejca.2015.11.016 10.4049/jimmunol.156.11.4154 10.1056/NEJMoa1412082 10.4049/jimmunol.175.1.177 10.1056/NEJMoa1507643 10.1056/NEJMoa1805131 10.1056/NEJMoa1613493 10.1016/S1470-2045(18)30006-8 10.1111/j.1600-065X.2008.00662.x 10.1038/328267a0 10.1038/nrc3239 10.1016/S1470-2045(16)30098-5 10.1007/978-3-319-48066-4_11 10.1186/s13046-019-1153-8 10.1016/j.immuni.2010.08.004 10.1016/S1470-2045(18)30765-4 10.1126/science.291.5502.319 10.1016/S1470-2045(15)70122-1 10.1016/S1470-2045(18)30778-2 10.1016/S1470-2045(09)70334-1 10.1016/S1470-2045(16)30364-3 10.1186/s13046-019-1085-3 10.1097/CMR.0000000000000251 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13046-019-1259-z |
| DatabaseName | Springer Nature Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-9966 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_d8eb374f8cb6425b95e04acf0c2955d7 PMC6567914 A590760056 31196207 10_1186_s13046_019_1259_z |
| Genre | Journal Article Review |
| GroupedDBID | --- 0R~ 29K 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 D-I DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M AAYXX AFFHD CITATION -5E -5G -A0 -BR 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c700t-eef293b82ae4d7579fe7fdb73260764ddcc69cca415c4cef5ba1b06674ad7d603 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 718 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000471625000005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1756-9966 0392-9078 |
| IngestDate | Fri Oct 03 12:53:22 EDT 2025 Tue Nov 04 01:51:05 EST 2025 Thu Dec 04 03:56:47 EST 2025 Sun Oct 19 00:04:31 EDT 2025 Tue Nov 11 10:07:27 EST 2025 Tue Nov 04 18:02:27 EST 2025 Thu May 22 20:58:49 EDT 2025 Thu Jan 02 22:59:30 EST 2025 Tue Nov 18 21:53:06 EST 2025 Sat Nov 29 03:43:18 EST 2025 Sat Sep 06 07:23:55 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | CTLA-4 Combination therapy PD-1 Immunotherapy |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c700t-eef293b82ae4d7579fe7fdb73260764ddcc69cca415c4cef5ba1b06674ad7d603 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2242809913?pq-origsite=%requestingapplication% |
| PMID | 31196207 |
| PQID | 2242809913 |
| PQPubID | 105475 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d8eb374f8cb6425b95e04acf0c2955d7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6567914 proquest_miscellaneous_2250644106 proquest_journals_2242809913 gale_infotracmisc_A590760056 gale_infotracacademiconefile_A590760056 gale_healthsolutions_A590760056 pubmed_primary_31196207 crossref_primary_10_1186_s13046_019_1259_z crossref_citationtrail_10_1186_s13046_019_1259_z springer_journals_10_1186_s13046_019_1259_z |
| PublicationCentury | 2000 |
| PublicationDate | 2019-06-13 |
| PublicationDateYYYYMMDD | 2019-06-13 |
| PublicationDate_xml | – month: 06 year: 2019 text: 2019-06-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of experimental & clinical cancer research |
| PublicationTitleAbbrev | J Exp Clin Cancer Res |
| PublicationTitleAlternate | J Exp Clin Cancer Res |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | H Nishimura (1259_CR83) 2001; 22 SP D'Angelo (1259_CR95) 2017; 35 MD Hellmann (1259_CR105) 2018; 378 A Ribas (1259_CR68) 2015; 16 SA Rosenberg (1259_CR1) 2014; 192 A Rotte (1259_CR13) 2018; 29 MJ Disselhorst (1259_CR108) 2019; 7 G Giaccone (1259_CR66) 2018; 19 D Cella (1259_CR100) 2019; 20 H Nishimura (1259_CR50) 2001; 291 RL Ferris (1259_CR58) 2016; 375 A Rittmeyer (1259_CR74) 2017; 389 BT Fife (1259_CR20) 2008; 224 C Robert (1259_CR69) 2015; 372 MJ Overman (1259_CR102) 2018; 36 PA Ascierto (1259_CR32) 2017; 18 SM Ansell (1259_CR53) 2015; 372 JS Weber (1259_CR91) 2016; 17 S Antonia (1259_CR103) 2016; 17 SJ Antonia (1259_CR107) 2016; 17 M Bhandaru (1259_CR9) 2017; 1 MR Migden (1259_CR80) 2018; 379 K Wing (1259_CR22) 2008; 322 EB Garon (1259_CR65) 2015; 372 EA Tivol (1259_CR82) 1995; 3 HA Tawbi (1259_CR90) 2018; 379 S George (1259_CR59) 2016; 2 JH Fraser (1259_CR29) 1999; 29 K Shitara (1259_CR71) 2018; 392 A Rotte (1259_CR12) 2018; 37 DP Carbone (1259_CR56) 2017; 376 F Bennett (1259_CR48) 2003; 170 AM Di Giacomo (1259_CR33) 2015; 26 MC Kirchberger (1259_CR94) 2016; 65 H Borghaei (1259_CR54) 2015; 373 MA Postow (1259_CR85) 2015; 372 A Rotte (1259_CR2) 2016 1259_CR79 HL Kaufman (1259_CR77) 2016; 17 MF Sanmamed (1259_CR5) 2015; 42 FS Hodi (1259_CR88) 2018; 19 Y Ishida (1259_CR39) 1992; 11 D Perkins (1259_CR17) 1996; 156 X Wang (1259_CR10) 2019; 38 C Robert (1259_CR37) 2011; 364 LQ Chow (1259_CR64) 2016; 34 H Schneider (1259_CR28) 2008; 3 P Darvin (1259_CR7) 2018; 50 JF Brunet (1259_CR16) 1987; 328 FS Hodi (1259_CR36) 2010; 363 FS Hodi (1259_CR92) 2016; 17 CS Fuchs (1259_CR70) 2018; 4 AM Intlekofer (1259_CR26) 2013; 94 LM Francisco (1259_CR44) 2010; 236 MF Sanmamed (1259_CR6) 2018; 175 JE Rosenberg (1259_CR73) 2016; 387 1259_CR81 MJ Overman (1259_CR101) 2017; 18 A Scherpereel (1259_CR109) 2019; 20 A Rotte (1259_CR4) 2015; 34 MF Krummel (1259_CR23) 1995; 182 A Meerveld-Eggink (1259_CR93) 2017; 28 S Chikuma (1259_CR27) 2005; 175 JS Weber (1259_CR52) 2015; 16 J Delyon (1259_CR57) 2018; 29 S Peters (1259_CR76) 2017; 35 J Brahmer (1259_CR55) 2015; 373 MD Hellmann (1259_CR104) 2017; 18 C Robert (1259_CR51) 2015; 372 RJ Motzer (1259_CR99) 2018; 378 SP D'Angelo (1259_CR112) 2018; 19 AM Eggermont (1259_CR34) 2016; 375 J Bellmunt (1259_CR62) 2017; 376 M Bhandaru (1259_CR30) 2019; 1904 RJ Motzer (1259_CR60) 2015; 373 ML Alegre (1259_CR18) 1996; 157 CA Chambers (1259_CR25) 1997; 7 ME Keir (1259_CR43) 2008; 26 GV Long (1259_CR89) 2017; 18 MC Kirchberger (1259_CR96) 2018; 9 CC Stamper (1259_CR21) 2001; 410 DB Johnson (1259_CR113) 2016; 375 YY Janjigian (1259_CR110) 2018; 36 N Ready (1259_CR106) 2019; 37 1259_CR61 JD Wolchok (1259_CR84) 2013; 369 A Rotte (1259_CR3) 2016 LM Francisco (1259_CR41) 2009; 206 K Boudadi (1259_CR111) 2018; 9 KM Hargadon (1259_CR11) 2018; 62 J Bellmunt (1259_CR63) 2017; 376 M Reck (1259_CR67) 2016; 375 A Mehta (1259_CR114) 2016; 26 Y Latchman (1259_CR42) 2001; 2 CU Blank (1259_CR97) 2018; 24 1259_CR31 JM Michot (1259_CR15) 2016; 54 DR Leach (1259_CR24) 1996; 271 JD Wolchok (1259_CR87) 2017; 377 JD Wolchok (1259_CR38) 2010; 11 SJ Antonia (1259_CR78) 2017; 377 CK Looi (1259_CR8) 2019; 38 AM Eggermont (1259_CR35) 2015; 16 H Nishimura (1259_CR49) 1999; 11 A Tarhini (1259_CR14) 2013; 2013 BM Carreno (1259_CR45) 2000; 165 HJ Hammers (1259_CR98) 2017; 35 1259_CR46 J Larkin (1259_CR86) 2015; 373 DM Pardoll (1259_CR19) 2012; 12 1259_CR40 LC Cappelli (1259_CR115) 2017; 76 L Fehrenbacher (1259_CR75) 2016; 387 TR Malek (1259_CR47) 2010; 33 YK Kang (1259_CR72) 2017; 390 |
| References_xml | – volume: 2 start-page: 261 issue: 3 year: 2001 ident: 1259_CR42 publication-title: Nat Immunol. doi: 10.1038/85330 – volume: 165 start-page: 1352 issue: 3 year: 2000 ident: 1259_CR45 publication-title: J Immunol. doi: 10.4049/jimmunol.165.3.1352 – volume: 24 start-page: 1655 issue: 11 year: 2018 ident: 1259_CR97 publication-title: Nat Med. doi: 10.1038/s41591-018-0198-0 – volume: 28 start-page: 862 issue: 4 year: 2017 ident: 1259_CR93 publication-title: Ann Oncol. doi: 10.1093/annonc/mdw692 – volume: 34 start-page: 115 issue: 1 year: 2015 ident: 1259_CR4 publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-014-9542-0 – volume: 18 start-page: 31 issue: 1 year: 2017 ident: 1259_CR104 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30624-6 – volume: 35 start-page: 2781 issue: 24 year: 2017 ident: 1259_CR76 publication-title: J Clin Oncol. doi: 10.1200/JCO.2016.71.9476 – volume: 192 start-page: 5451 issue: 12 year: 2014 ident: 1259_CR1 publication-title: J Immunol. doi: 10.4049/jimmunol.1490019 – volume: 182 start-page: 459 issue: 2 year: 1995 ident: 1259_CR23 publication-title: J Exp Med. doi: 10.1084/jem.182.2.459 – volume: 236 start-page: 219 issue: 1 year: 2010 ident: 1259_CR44 publication-title: Immunological Reviews. doi: 10.1111/j.1600-065X.2010.00923.x – volume: 11 start-page: 141 issue: 2 year: 1999 ident: 1259_CR49 publication-title: Immunity. doi: 10.1016/S1074-7613(00)80089-8 – volume: 94 start-page: 25 issue: 1 year: 2013 ident: 1259_CR26 publication-title: J Leukoc Biol. doi: 10.1189/jlb.1212621 – volume: 76 start-page: 43 issue: 1 year: 2017 ident: 1259_CR115 publication-title: Ann Rheum Dis. doi: 10.1136/annrheumdis-2016-209595 – volume: 17 start-page: 299 issue: 3 year: 2016 ident: 1259_CR103 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)00544-6 – volume: 36 start-page: 773 issue: 8 year: 2018 ident: 1259_CR102 publication-title: J Clin Oncol. doi: 10.1200/JCO.2017.76.9901 – volume: 378 start-page: 1277 issue: 14 year: 2018 ident: 1259_CR99 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1712126 – volume: 375 start-page: 1856 issue: 19 year: 2016 ident: 1259_CR58 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1602252 – volume: 377 start-page: 1919 issue: 20 year: 2017 ident: 1259_CR78 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1709937 – volume: 322 start-page: 271 issue: 5899 year: 2008 ident: 1259_CR22 publication-title: Science. doi: 10.1126/science.1160062 – volume-title: Interleukin-2. Immunotherapy of melanoma year: 2016 ident: 1259_CR2 doi: 10.1007/978-3-319-48066-4 – ident: 1259_CR79 doi: 10.1001/jamaoncol.2017.2411 – volume: 26 start-page: 798 issue: 4 year: 2015 ident: 1259_CR33 publication-title: Ann Oncol. doi: 10.1093/annonc/mdu577 – volume: 19 start-page: 347 issue: 3 year: 2018 ident: 1259_CR66 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30062-7 – volume: 364 start-page: 2517 issue: 26 year: 2011 ident: 1259_CR37 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1104621 – volume: 389 start-page: 255 issue: 10066 year: 2017 ident: 1259_CR74 publication-title: Lancet. doi: 10.1016/S0140-6736(16)32517-X – volume: 9 start-page: 28561 issue: 47 year: 2018 ident: 1259_CR111 publication-title: Oncotarget. doi: 10.18632/oncotarget.25564 – volume: 375 start-page: 1749 issue: 18 year: 2016 ident: 1259_CR113 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1609214 – volume: 3 start-page: e3842 issue: 12 year: 2008 ident: 1259_CR28 publication-title: PLoS One. doi: 10.1371/journal.pone.0003842 – volume: 376 start-page: 2304 issue: 23 year: 2017 ident: 1259_CR62 publication-title: N Engl J Med. – volume: 29 start-page: 71 issue: 1 year: 2018 ident: 1259_CR13 publication-title: Ann Oncol. doi: 10.1093/annonc/mdx686 – volume: 17 start-page: 943 issue: 7 year: 2016 ident: 1259_CR91 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30126-7 – volume: 369 start-page: 122 issue: 2 year: 2013 ident: 1259_CR84 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1302369 – volume: 271 start-page: 1734 issue: 5256 year: 1996 ident: 1259_CR24 publication-title: Science. doi: 10.1126/science.271.5256.1734 – volume: 170 start-page: 711 issue: 2 year: 2003 ident: 1259_CR48 publication-title: J Immunol. doi: 10.4049/jimmunol.170.2.711 – volume: 65 start-page: 182 year: 2016 ident: 1259_CR94 publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2016.07.003 – volume: 7 start-page: 885 issue: 6 year: 1997 ident: 1259_CR25 publication-title: Immunity. doi: 10.1016/S1074-7613(00)80406-9 – volume: 392 start-page: 123 issue: 10142 year: 2018 ident: 1259_CR71 publication-title: Lancet. doi: 10.1016/S0140-6736(18)31257-1 – volume: 175 start-page: 313 issue: 2 year: 2018 ident: 1259_CR6 publication-title: Cell. doi: 10.1016/j.cell.2018.09.035 – volume: 375 start-page: 1845 issue: 19 year: 2016 ident: 1259_CR34 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1611299 – volume: 378 start-page: 2093 issue: 22 year: 2018 ident: 1259_CR105 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1801946 – volume: 18 start-page: 1182 issue: 9 year: 2017 ident: 1259_CR101 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30422-9 – volume: 390 start-page: 2461 issue: 10111 year: 2017 ident: 1259_CR72 publication-title: Lancet. doi: 10.1016/S0140-6736(17)31827-5 – volume: 363 start-page: 711 issue: 8 year: 2010 ident: 1259_CR36 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1003466 – ident: 1259_CR61 doi: 10.1200/JCO.19.00315 – volume: 157 start-page: 4762 issue: 11 year: 1996 ident: 1259_CR18 publication-title: J Immunol. doi: 10.4049/jimmunol.157.11.4762 – volume: 11 start-page: 3887 issue: 11 year: 1992 ident: 1259_CR39 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 16 start-page: 375 issue: 4 year: 2015 ident: 1259_CR52 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)70076-8 – volume: 373 start-page: 1803 issue: 19 year: 2015 ident: 1259_CR60 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1510665 – ident: 1259_CR46 doi: 10.1126/science.aav7062 – volume: 42 start-page: 640 issue: 4 year: 2015 ident: 1259_CR5 publication-title: Semin Oncol. doi: 10.1053/j.seminoncol.2015.05.014 – volume: 375 start-page: 1823 issue: 19 year: 2016 ident: 1259_CR67 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1606774 – volume: 37 start-page: 992 issue: 12 year: 2019 ident: 1259_CR106 publication-title: J Clin Oncol. doi: 10.1200/JCO.18.01042 – volume: 37 start-page: 262 issue: 1 year: 2018 ident: 1259_CR12 publication-title: J Exp Clin Cancer Res. doi: 10.1186/s13046-018-0937-6 – ident: 1259_CR40 doi: 10.1007/978-3-319-48066-4_12 – volume: 3 start-page: 541 issue: 5 year: 1995 ident: 1259_CR82 publication-title: Immunity. doi: 10.1016/1074-7613(95)90125-6 – ident: 1259_CR81 doi: 10.1200/JCO.19.00318 – volume: 18 start-page: 1202 issue: 9 year: 2017 ident: 1259_CR89 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30428-X – volume: 4 start-page: e180013 issue: 5 year: 2018 ident: 1259_CR70 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2018.0013 – volume: 379 start-page: 722 issue: 8 year: 2018 ident: 1259_CR90 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1805453 – volume: 22 start-page: 265 issue: 5 year: 2001 ident: 1259_CR83 publication-title: Trends Immunol. doi: 10.1016/S1471-4906(01)01888-9 – volume: 373 start-page: 23 issue: 1 year: 2015 ident: 1259_CR86 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1504030 – volume: 372 start-page: 311 issue: 4 year: 2015 ident: 1259_CR53 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1411087 – volume: 35 start-page: 3851 issue: 34 year: 2017 ident: 1259_CR98 publication-title: J Clin Oncol. doi: 10.1200/JCO.2016.72.1985 – volume: 373 start-page: 123 issue: 2 year: 2015 ident: 1259_CR55 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1504627 – volume: 29 start-page: 1067 issue: 4 year: 2018 ident: 1259_CR57 publication-title: Ann Oncol. doi: 10.1093/annonc/mdy006 – volume: 26 start-page: 677 year: 2008 ident: 1259_CR43 publication-title: Annu Rev Immunol. doi: 10.1146/annurev.immunol.26.021607.090331 – volume: 19 start-page: 1480 issue: 11 year: 2018 ident: 1259_CR88 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30700-9 – volume: 35 start-page: 226 issue: 2 year: 2017 ident: 1259_CR95 publication-title: J Clin Oncol. doi: 10.1200/JCO.2016.67.9258 – volume: 29 start-page: 838 issue: 3 year: 1999 ident: 1259_CR29 publication-title: Eur J Immunol. doi: 10.1002/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P – volume: 372 start-page: 2018 issue: 21 year: 2015 ident: 1259_CR65 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1501824 – volume: 372 start-page: 2521 issue: 26 year: 2015 ident: 1259_CR69 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1503093 – volume: 377 start-page: 1345 issue: 14 year: 2017 ident: 1259_CR87 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1709684 – volume: 34 start-page: 3838 issue: 32 year: 2016 ident: 1259_CR64 publication-title: J Clin Oncol. doi: 10.1200/JCO.2016.68.1478 – volume: 1 start-page: 1 issue: 2 year: 2017 ident: 1259_CR9 publication-title: Journal of Dermatologic Research and Therapy. doi: 10.14302/issn.2471-2175.jdrt-17-1760 – volume: 372 start-page: 2006 issue: 21 year: 2015 ident: 1259_CR85 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1414428 – volume: 17 start-page: 1558 issue: 11 year: 2016 ident: 1259_CR92 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30366-7 – volume: 2013 start-page: 857519 year: 2013 ident: 1259_CR14 publication-title: Scientifica (Cairo). – volume: 50 start-page: 165 issue: 12 year: 2018 ident: 1259_CR7 publication-title: Exp Mol Med. doi: 10.1038/s12276-018-0191-1 – volume: 387 start-page: 1909 issue: 10031 year: 2016 ident: 1259_CR73 publication-title: Lancet. doi: 10.1016/S0140-6736(16)00561-4 – volume: 2 start-page: 1179 issue: 9 year: 2016 ident: 1259_CR59 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2016.0775 – volume: 62 start-page: 29 year: 2018 ident: 1259_CR11 publication-title: Int Immunopharmacol. doi: 10.1016/j.intimp.2018.06.001 – volume: 376 start-page: 1015 issue: 11 year: 2017 ident: 1259_CR63 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1613683 – volume: 387 start-page: 1837 issue: 10030 year: 2016 ident: 1259_CR75 publication-title: Lancet. doi: 10.1016/S0140-6736(16)00587-0 – volume: 1904 start-page: 83 year: 2019 ident: 1259_CR30 publication-title: Methods Mol Biol. doi: 10.1007/978-1-4939-8958-4_4 – volume: 9 start-page: 28903 issue: 48 year: 2018 ident: 1259_CR96 publication-title: Oncotarget. doi: 10.18632/oncotarget.25627 – volume: 36 start-page: 2836 issue: 28 year: 2018 ident: 1259_CR110 publication-title: J Clin Oncol. doi: 10.1200/JCO.2017.76.6212 – volume: 18 start-page: 611 issue: 5 year: 2017 ident: 1259_CR32 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30231-0 – volume: 16 start-page: 908 issue: 8 year: 2015 ident: 1259_CR68 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)00083-2 – volume: 7 start-page: 260 issue: 3 year: 2019 ident: 1259_CR108 publication-title: Lancet Respir Med. doi: 10.1016/S2213-2600(18)30420-X – volume: 206 start-page: 3015 issue: 13 year: 2009 ident: 1259_CR41 publication-title: J Exp Med. doi: 10.1084/jem.20090847 – volume: 410 start-page: 608 issue: 6828 year: 2001 ident: 1259_CR21 publication-title: Nature. doi: 10.1038/35069118 – volume: 54 start-page: 139 year: 2016 ident: 1259_CR15 publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2015.11.016 – volume: 156 start-page: 4154 issue: 11 year: 1996 ident: 1259_CR17 publication-title: J Immunol. doi: 10.4049/jimmunol.156.11.4154 – volume: 372 start-page: 320 issue: 4 year: 2015 ident: 1259_CR51 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1412082 – volume-title: Interferon-a2b. Immunotherapy of melanoma year: 2016 ident: 1259_CR3 doi: 10.1007/978-3-319-48066-4 – volume: 175 start-page: 177 issue: 1 year: 2005 ident: 1259_CR27 publication-title: J Immunol. doi: 10.4049/jimmunol.175.1.177 – volume: 373 start-page: 1627 issue: 17 year: 2015 ident: 1259_CR54 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1507643 – volume: 379 start-page: 341 issue: 4 year: 2018 ident: 1259_CR80 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1805131 – volume: 376 start-page: 2415 issue: 25 year: 2017 ident: 1259_CR56 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1613493 – volume: 19 start-page: 416 issue: 3 year: 2018 ident: 1259_CR112 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30006-8 – volume: 224 start-page: 166 year: 2008 ident: 1259_CR20 publication-title: Immunol Rev. doi: 10.1111/j.1600-065X.2008.00662.x – volume: 328 start-page: 267 issue: 6127 year: 1987 ident: 1259_CR16 publication-title: Nature. doi: 10.1038/328267a0 – volume: 12 start-page: 252 issue: 4 year: 2012 ident: 1259_CR19 publication-title: Nat Rev Cancer. doi: 10.1038/nrc3239 – volume: 17 start-page: 883 issue: 7 year: 2016 ident: 1259_CR107 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30098-5 – ident: 1259_CR31 doi: 10.1007/978-3-319-48066-4_11 – volume: 38 start-page: 162 issue: 1 year: 2019 ident: 1259_CR8 publication-title: J Exp Clin Cancer Res. doi: 10.1186/s13046-019-1153-8 – volume: 33 start-page: 153 issue: 2 year: 2010 ident: 1259_CR47 publication-title: Immunity. doi: 10.1016/j.immuni.2010.08.004 – volume: 20 start-page: 239 issue: 2 year: 2019 ident: 1259_CR109 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30765-4 – volume: 291 start-page: 319 issue: 5502 year: 2001 ident: 1259_CR50 publication-title: Science. doi: 10.1126/science.291.5502.319 – volume: 16 start-page: 522 issue: 5 year: 2015 ident: 1259_CR35 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)70122-1 – volume: 20 start-page: 297 issue: 2 year: 2019 ident: 1259_CR100 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30778-2 – volume: 11 start-page: 155 issue: 2 year: 2010 ident: 1259_CR38 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(09)70334-1 – volume: 17 start-page: 1374 issue: 10 year: 2016 ident: 1259_CR77 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30364-3 – volume: 38 start-page: 87 issue: 1 year: 2019 ident: 1259_CR10 publication-title: J Exp Clin Cancer Res. doi: 10.1186/s13046-019-1085-3 – volume: 26 start-page: 319 issue: 3 year: 2016 ident: 1259_CR114 publication-title: Melanoma Res. doi: 10.1097/CMR.0000000000000251 |
| SSID | ssj0061919 |
| Score | 2.6774337 |
| SecondaryResourceType | review_article |
| Snippet | Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses.... Abstract Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses.... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 255 |
| SubjectTerms | Advances in Cancer Immunotherapy Amino acids Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Biomedical and Life Sciences Biomedicine Breast cancer Cancer Cancer Research Cancer therapies Care and treatment Cervical cancer Chemotherapy Clinical Trials as Topic Colorectal cancer Combination therapy CTLA-4 CTLA-4 Antigen - antagonists & inhibitors Gastric cancer Genetic aspects Humans Immunology Immunotherapy Kidney cancer Ligands Liver cancer Lung cancer Lymphocytes Lymphoma Medical research Melanoma Mesothelioma Metastasis Molecular Targeted Therapy Monoclonal antibodies Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - immunology Neoplasms - metabolism Oncology PD-1 Programmed Cell Death 1 Receptor - antagonists & inhibitors Proteins Review Studies T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - metabolism Targeted cancer therapy Treatment Outcome Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXVMorUFojISGBotqJHccntBQqDqXqoaDeLD_VCpRFu9se-uuZcbKhKQIuvcYTxR7PeL7J2J8Jee0Apoaay1L6iKTaLpWuZqxMUYbAlXIh_4f8dqiOjtrTU3187aov3BPW0wP3itsLLaR7SqTWO4DK0mkZmbA-MV9p-Ew-Rw6oZ51M9WswZAVcDzVM3jZ7S44FQEibkfpf6vJqEoUyWf-fS_K1mHRzv-SNommORQeb5MEAIums7_xDcid2W-Tel6FM_oi8By-HjDcrnc4T3T85nJWC2i7Q448lpw4i2HfAfRQQKx23mqOkRyNYPCZfDz6d7H8uh5sSSq8YW5UxJgjbrq1sFEFJpVNUKTgF2IypRoTgfaNhriBae-Fjks5yh9tbhQ0qNKx-Qja6eRefEYqM97Wvq-QEUsFJRAgwjc4Gbi2vmoKwteaMH2jE8TaLHyanE21jemUbULZBZZurgrwdX_nZc2j8S_gDTscoiPTX-QEYhRmMwvzPKAqyi5Np-rOkoxObmdS5EilhGG-yBLoxdN_b4TQCKAEJsSaS2xNJcD8_bV4bjBncf2kAF1UtYG9eF-TV2Ixv4pa2Ls4vUAa5AgWk5AV52tvXOOiaw8JYMRiHmljeRCvTlu78LJODAz5XmouCvFvb6O9u_VXpz29D6S_I_Qo9DC92qrfJxmpxEV-Su_5ydb5c7GT__AV5oTtP priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwEB5BQYhL2SFQIEhISKCodmLHyQm9FioOpaqgVL1Z8QYVKK9675VDfz0zzlJSFgmu8Viyx7Nmxp8BnhsMU13BZSatJ1BtEzJTMJYFL53jShkX_0Me7qq9veroqN7v73Evh273oSQZLXVU66rcXHIq4mHqS_D9ss7OLsMV9HYVaeOHj4eD-cWEgNd9-fK30yYOKOL0_2qNf3JHF1slL9RLoxvaufFfG7gJ633Umc46MbkFl3x7G6697-vqd-A1mgVMkeMppfOQbh_szjKRNq1L999kPDXo8r5ioJhiiJuOvelEaUlqFnfh087bg-13Wf-0QmYVY6vM-4B-3lR544VTUtXBq-CMwmCOqVI4Z21Z4-Gie7fC-iBNww31w4rGKVey4h6stfPWP4CUIPILW-TBCMKOkxRS4LmbxvGm4XmZABv4rW2PO07PX3zTMf-oSt0xRiNjNDFGnyXwcpxy0oFu_I14iw5xJCS87Phhvvise_XTrvKmUCJU1mDCJU0tPRONDczmNQqrSuApiYDuLp-OWq9nso6lS4nbeBEpSO9x-bbpry8gEwhBa0K5MaFEfbXT4UHMdG8vlhoDqbzCYJ0XCTwbh2km9cC1fn5KNAQuKDCHT-B-J5XjpguOljRnuA81kdcJV6Yj7fGXiCaOAb2quUjg1SC158v6I9Mf_hP1I7iek9jTk0_FBqytFqf-MVy131fHy8WTqL4_AAOdPzM priority: 102 providerName: Springer Nature |
| Title | Combination of CTLA-4 and PD-1 blockers for treatment of cancer |
| URI | https://link.springer.com/article/10.1186/s13046-019-1259-z https://www.ncbi.nlm.nih.gov/pubmed/31196207 https://www.proquest.com/docview/2242809913 https://www.proquest.com/docview/2250644106 https://pubmed.ncbi.nlm.nih.gov/PMC6567914 https://doaj.org/article/d8eb374f8cb6425b95e04acf0c2955d7 |
| Volume | 38 |
| WOSCitedRecordID | wos000471625000005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1756-9966 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061919 issn: 1756-9966 databaseCode: RBZ dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1756-9966 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061919 issn: 1756-9966 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1756-9966 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061919 issn: 1756-9966 databaseCode: M~E dateStart: 20080101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1756-9966 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061919 issn: 1756-9966 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest customDbUrl: eissn: 1756-9966 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061919 issn: 1756-9966 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1756-9966 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061919 issn: 1756-9966 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1756-9966 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061919 issn: 1756-9966 databaseCode: RSV dateStart: 20080501 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RLUJceD8CZQkSEhLIah52nJyqbWkFUrtalVKVkxU_AhUoW3a3HPrrmfF6U1JEL1wiJZ5Isf155huPMwPwWiNNtXkqmDCOkmrrhuk8SVjjhLWplNr6fcjjfTkelycn1SRsuM3DscqVTvSK2k4N7ZFvoqnJSqQzab519pNR1SiKroYSGmuwTpnK-ADWt3fHk8OVLkbvwJf2QBtZMGL2Ia6ZlsXmPKWgILrSVA5AVOyiZ5l8Av-_1fQfdurqGcorgVRvn_bu_m_P7sGdwEzj0RJK9-GGax_ArYMQe38IW6g60I32MxlPm3jnaH_EeFy3Np68Z2ms0Sx-RzIZIw2Ou_PrJGkIWbNH8Hlv92jnAwvlF5iRSbJgzjXIBXSZ1Y5bKWTVONlYLZHwJbLg1hpTVAgApACGG9cIXaeazszy2kpbJPljGLTT1j2FmNLo5ybPGs0pv5wg2oHY0LVN6zrNigiS1dArE3KTU4mMH8r7KGWhlrOlcLYUzZa6iOBt98rZMjHHdcLbNJ-dIOXU9g-ms68qLFFlS6dzyZvSaHTKhK6ES3htmsRkFQJaRvCS0KCWP6h2mkGNROXDmwK78cZLkG7Azzd1-MUBB4GybPUkN3qSuKZNv3kFFRV0ylxd4iSCV10zvUnn5Fo3PScZSkDI0c-P4MkSoF2nc1whRZZgP2QPur1R6be0p998xnEk_bJKeQTvViC__Kx_Dvqz6zvxHG5ntPioDlS-AYPF7Ny9gJvm1-J0PhvCmjyR_loOw6Ie-v0SvJt8PJh8wbvDT8e_AXfiUaY |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCF92OhUCOBkEBW4ySOkwOqlpaqVberHha0NxM_AitQUna3IPqj-I3MOI-SInrrgWs8iWxnZr4Zz3iGkOcazFQbccGEcVhUWxdMR0HACies5VJq688hP4zkeJxOp9nhCvnV3oXBtMpWJ3pFbSuDZ-QbADVhCuYMjzaPvjHsGoXR1baFRs0W--7nD3DZFm_2tuH_vgjDnXeTrV3WdBVgRgbBkjlXAMTpNMxdbKWQWeFkYbUEOwZ8-thaY5IM1gXIZmLjCqFzrjEVNM6ttEkQwXcvkcugxyWmkMlp5-CBL-IbiQAiJwz9iCaKytNkY8ExBAmOOzYfEBk76eGgbxfwNyj8gYpnMzbPhG09Gu7c_N_28Ra50djddFgLym2y4so75OpBk1lwl2yCYtSz-miUVgXdmoyGLKZ5aenhNuNUA-h_AVOZgpFPu-x8pDQoN_N75P2FTP8-WS2r0j0kFJsERCYKCx1j9TyBRhVwvs4tz3MeJgMStL9amabyOjYA-aq8B5YmquYOBdyhkDvUyYC86l45qsuOnEf8FvmnI8SK4f5BNf-kGgWkbOp0JOMiNRpcTqEz4YI4N0VgwgzEVQ7IOnKfqq_fdnpPDUXmg7cClvHSU6Dmg-mbvLnAAZuANcR6lGs9StBYpj_csqZqNOZCnfLlgDzrhvFNzAIsXXWMNFheMeYBfOJBLRDdoiMOWBIGsA7ZE5XervRHytlnX08dXBqZ8XhAXrdCdTqtf276o_MXsU6u7U4ORmq0N95_TK6HKPjY8SpaI6vL-bF7Qq6Y78vZYv7UqxBKPl60rP0Gz-uqNg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELagoKov3C2hLQ0SEhIoqp3YcfKEti0rEMtqJUrVNyu-oAJlq90tD_31nXEOSDkkxGs8juLxeI7M-BtCnmtwU23GRCKMQ1Bt7ROdUZp4J6xlUmob_kOeTOR0WpyelrO2z-myq3bvUpLNnQZEaapX--fWN0e8yPeXDBN6EAYjlL8ok8ub5BbHnkEYrn886VQxBAesbFOZv502MEYBs_9XzfyTabpeNnktdxpM0vjufy_mHrnTeqPxqBGf--SGqx-Q9Q9tvv0heQ3qAkLnsHvx3MeHx5NRwuOqtvHsKGGxBlP4FRzIGFzfuK9ZR0qD0rR4RD6N3xwfvk3alguJkZSuEuc82H9dpJXjVgpZeie91RKcPCpzbq0xeQmbDmbfcOO80BXTWCfLKyttTrNNslbPa_eYxAidn5ks9ZojppxAVwPkQVeWVRVL84jQjvfKtHjk2BbjmwpxSZGrhjEKGKOQMeoyIi_7KecNGMffiA9wQ3tCxNEOD-aLz6o9lsoWTmeS-8JoCMSELoWjvDKemrQEIZYR2UNxUM2l1F4bqJEoQ0pTwDJeBArUB_D5pmqvNQATEFlrQLkzoIRzbIbDncipVo8sFThYaQFOPMsi8qwfxplYG1e7-QXSIOggiD-8YquR0H7RGQMNm1JYhxzI7oArw5H67EtAGQdHX5aMR-RVJ8E_PuuPTH_yT9R7ZH12NFaTd9P322QjxROAXaGyHbK2Wly4XXLbfF-dLRdPw6m-AozrSvs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combination+of+CTLA-4+and+PD-1+blockers+for+treatment+of+cancer&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Rotte%2C+Anand&rft.date=2019-06-13&rft.pub=BioMed+Central+Ltd&rft.issn=0392-9078&rft.volume=38&rft.issue=1&rft_id=info:doi/10.1186%2Fs13046-019-1259-z&rft.externalDBID=n%2Fa&rft.externalDocID=A590760056 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |